UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

The New England journal of medicine, 2014-12, Vol.371 (23), p.2167-2177

2014

Volltextzugriff (PDF)

The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional study

Supportive care in cancer, 2014-01, Vol.22 (1), p.181-187

2014

Volltextzugriff (PDF)

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

The New England journal of medicine, 2013-06, Vol.368 (25), p.2385-2394

2013

Volltextzugriff (PDF)

Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA

Future oncology (London, England), 2021-07, Vol.17 (21), p.2759-2768

2021

Volltextzugriff (PDF)

Real‐world effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in US clinical practice

Cancer reports, 2023-01, Vol.6 (1), p.e1679-n/a

2023

Volltextzugriff (PDF)

Patient characteristics and treatment patterns in chronic myeloid leukemia: evidence from a multi-country retrospective medical record chart review study

International journal of hematology, 2012-03, Vol.95 (3), p.263-273

2012

Volltextzugriff (PDF)

Corrigendum to “Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies” [Breast 41S1 (2018) S11–12]

Breast (Edinburgh), 2020-02, Vol.49, p.131-131

2020

Volltextzugriff (PDF)

Effect of subcutaneous methylnaltrexone on patient-reported constipation symptoms

Value in health, 2011, Vol.14 (1), p.177-183

2011

Volltextzugriff (PDF)

Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study

International journal of hematology, 2012-05, Vol.95 (5), p.535-544

2012

Volltextzugriff (PDF)

Methylnaltrexone in the Treatment of Opioid-Induced Constipation in Cancer Patients Receiving Palliative Care: Willingness-to-Pay and Cost-Benefit Analysis

Journal of pain and symptom management, 2011, Vol.41 (1), p.104-115

2011

Volltextzugriff (PDF)

Real-world effectiveness of lenvatinib monotherapy among previously treated unresectable hepatocellular carcinoma patients in United States clinical practices

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e16129-e16129

2021

Volltextzugriff (PDF)

Impact of Constipation on Opioid Use Patterns, Health Care Resource Utilization, and Costs in Cancer Patients on Opioid Therapy

Journal of pain & palliative care pharmacotherapy, 2009, Vol.23 (3), p.231-241

2009

Volltextzugriff (PDF)

Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients treated in United States clinical practices

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.273-273

2021

Volltextzugriff (PDF)

Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study

Breast (Edinburgh), 2019-02, Vol.43, p.22-27

2019

Volltextzugriff (PDF)

Patient-reported Quality of Life and Treatment Satisfaction in Patients With HR+/HER2– Advanced/Metastatic Breast Cancer

Clinical therapeutics, 2017-08, Vol.39 (8), p.1719-1728

2017

Volltextzugriff (PDF)

Constipation in Persons Receiving Hospice Care

Journal of pain and symptom management, 2010-12, Vol.40 (6), p.810-820

2010

Volltextzugriff (PDF)

Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer

Breast cancer research and treatment, 2017-11, Vol.166 (1), p.167-177

2017

Volltextzugriff (PDF)

PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy-Safety and Efficacy in Asian Patients

Journal of global oncology, 2017-08, Vol.3 (4), p.289-303

2017

Volltextzugriff (PDF)

Real-World Effectiveness of Lenvatinib in Hepatocellular Carcinoma Patients with Nonalcoholic Steatohepatitis

Clinical gastroenterology and hepatology, 2023-03, Vol.21 (3), p.830-831.e1

2023

Volltextzugriff (PDF)

Subcutaneous Methylnaltrexone for Treatment of Opioid-Induced Constipation in Patients With Chronic, Nonmalignant Pain: A Randomized Controlled Study

The journal of pain, 2011-05, Vol.12 (5), p.554-562

2011

Volltextzugriff (PDF)

Palbociclib plus endocrine therapy in older women with HR+/HER2– advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies

European journal of cancer (1990), 2018-09, Vol.101, p.123-133

2018

Volltextzugriff (PDF)

Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study

Journal of global oncology, 2019-05, Vol.5 (5), p.JGO1800239

2019

Volltextzugriff (PDF)

Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study

Journal of global oncology, 2019-05, Vol.5 (5), p.1-19

2019

Volltextzugriff (PDF)

Breast cancer specific quality of life in HR+/HER2- advanced/metastatic breast cancer patients in a real-world setting

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.554-554

2016

Volltextzugriff (PDF)

Treatment satisfaction in women receiving palbociclib combination therapies for advanced/metastatic breast cancer

Future oncology (London, England), 2019-01, Vol.15 (2), p.141-150

2019

Volltextzugriff (PDF)

1 – 25 von 62

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(54)
Mit Volltextzugriff
(52)

Publikationsform

Sprache

Englisch
(62)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(34)
Science & Technology
(34)
Humans
(26)
Female
(22)
Middle Aged
(19)
Oncology
(19)
Male
(17)
Adult
(16)
Aged
(14)
Treatment Outcome
(11)
Health Care Sciences & Services
(9)
Patients
(9)
Quality Of Life
(9)
Retrospective Studies
(8)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(6)
Biological And Medical Sciences
(6)
Breast Cancer
(6)
Cancer Therapies
(6)
General & Internal Medicine
(6)
Medical Sciences
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional study

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA

Real‐world effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in US clinical practice

Patient characteristics and treatment patterns in chronic myeloid leukemia: evidence from a multi-country retrospective medical record chart review study

Corrigendum to “Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies” [Breast 41S1 (2018) S11–12]

Effect of subcutaneous methylnaltrexone on patient-reported constipation symptoms

Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study

Methylnaltrexone in the Treatment of Opioid-Induced Constipation in Cancer Patients Receiving Palliative Care: Willingness-to-Pay and Cost-Benefit Analysis

Real-world effectiveness of lenvatinib monotherapy among previously treated unresectable hepatocellular carcinoma patients in United States clinical practices

Impact of Constipation on Opioid Use Patterns, Health Care Resource Utilization, and Costs in Cancer Patients on Opioid Therapy

Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients treated in United States clinical practices

Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study

Patient-reported Quality of Life and Treatment Satisfaction in Patients With HR+/HER2– Advanced/Metastatic Breast Cancer

Constipation in Persons Receiving Hospice Care

Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer

PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy-Safety and Efficacy in Asian Patients

Real-World Effectiveness of Lenvatinib in Hepatocellular Carcinoma Patients with Nonalcoholic Steatohepatitis

Subcutaneous Methylnaltrexone for Treatment of Opioid-Induced Constipation in Patients With Chronic, Nonmalignant Pain: A Randomized Controlled Study

Palbociclib plus endocrine therapy in older women with HR+/HER2– advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies

Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study

Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study

Breast cancer specific quality of life in HR+/HER2- advanced/metastatic breast cancer patients in a real-world setting

Treatment satisfaction in women receiving palbociclib combination therapies for advanced/metastatic breast cancer

Suchergebnisse filtern